{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T01:04:14Z","timestamp":1772931854833,"version":"3.50.1"},"reference-count":64,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PNT"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Hydrophilic drugs are poor applicants for brain targeting via oral route\ndue to the presence of a blood-brain barrier that allows only small lipophilic molecules to freely\naccess the brain. Due to unique anatomical connections between the nasal cavity and the brain,\nintranasal administration can be explored for drug delivery to the brain directly that circumvents\nthe blood-brain barrier too.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>Zolmitriptan is a widely used antimigraine drug, and its brain targeting by nasal route\nin the form of mucoadhesive nanoparticles is more effective in migraine treatment as it provides\nfast relief and good bioavailability as compared to its oral drug delivery. In the present study,\nzolmitriptan mucoadhesive nanoparticles were prepared to improve the bioavailability and brain\ntargeting for the better management of Migraine attacks.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The mucoadhesive polymeric nanoparticles of zolmitriptan were formulated by a modified\nionic gelation method using thiolated chitosan. The pharmacokinetic parameters were counted\nin male Wistar rats by intranasal and oral delivery of the anti-migraine drug zolmitriptan and compared\nstatistically. The concentration of zolmitriptan in the blood plasma and brain samples was\ndetermined by using the liquid-liquid extraction method followed by a reversed-phase highperformance\nliquid chromatography (RP-HPLC) analysis. The pharmacodynamic analysis was\nconducted in adult male Swiss albino mice by behavioral models, a light\/dark box model, and acetic\nacid-induced writhing (abdominal stretching or constriction). These tests were used to reproduce\nthe important associated symptoms of migraine viz. hyperalgesia (nociceptive sensitization)\nand photophobia to assess the therapeutic potential of intranasal delivery of nanoparticles antimigraine\nactivity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The absolute bioavailability accessed for Zolmitriptan nanoparticles by IN route was\nfound to be very high (193%), suggesting that the sufficient amount of drug transported by nanoparticles\nand DTE ratio was calculated as 2.8. Moreover, it revealed better nose-to-brain transport\nby zolmitriptan nanoparticles as compared to oral delivery in male Wistar rats. A significant increase\nin the tolerance capacity of animals to bright light and a fall in the number of stretching in\nmice suggested the better management of migraine-associated symptoms by the zolmitriptan nanoparticles.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Thus, the present study confers the significance of nasal drug delivery for brain targeting\nof zolmitriptan nanoparticles for the treatment of migraine.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2211738510666220303160414","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T06:46:47Z","timestamp":1646376407000},"page":"113-124","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of Brain Targeting Potential of Zolmitriptan Mucoadhesive\nNanoparticles for Intranasal Drug Delivery"],"prefix":"10.2174","volume":"10","author":[{"given":"Sunena","family":"Jha","sequence":"first","affiliation":[{"name":"Geeta Institute of Pharmacy, Panipat 132145, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinanath","family":"Mishra","sequence":"additional","affiliation":[{"name":"Chaudhary Bansi Lal University, Bhiwani 127021,\nHaryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2174\/157488909787002555","volume":"4","author":"Belv\u00eds R.","year":"2009","unstructured":"Belv\u00eds R.; Pagonabarraga J.; Kulisevsky J.; Individual triptan selection in migraine attack therapy. Recent Patents CNS Drug Discov 2009,4(1),70-81","journal-title":"Recent Patents CNS Drug Discov"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/head.13459","volume":"59","author":"Buse D.C.","year":"2019","unstructured":"Buse D.C.; Greisman J.D.; Baigi K.; Lipton R.B.; Migraine progression: A systematic review. Headache 2019,59(3),306-338","journal-title":"Headache"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/j.1468-2982.2007.01476.x","volume":"27","author":"Hamel E.","year":"2007","unstructured":"Hamel E.; Currents H.; Serotonin and migraine: Biology and clinical implications. Cephalalgia 2007,27(11),1293-1300","journal-title":"Cephalalgia"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2174\/1871527313666140414120956","volume":"13","author":"Girotra P.","year":"2014","unstructured":"Girotra P.; Singh S.K.; Saini D.; Disentangling the intricacies of migraine: A review. CNS Neurol Disord Drug Targets 2014,13(5),776-791","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=5","first-page":"S23","volume":"25","author":"Peters G.L.","year":"2019","unstructured":"Peters G.L.; Migraine overview and summary of current and emerging treatment options. Am J Manag Care 2019,25(2)(Suppl.),S23-S34","journal-title":"Am J Manag Care"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/0333102418793642","volume":"39","author":"Deen M.","year":"2019","unstructured":"Deen M.; Hougaard A.; Hansen H.D.; Migraine is associated with high brain 5-HT levels as indexed by 5-HT4 receptor binding. Cephalalgia 2019,39(4),526-532","journal-title":"Cephalalgia"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1021\/jm00018a016","volume":"38","author":"Glen R.C.","year":"1995","unstructured":"Glen R.C.; Martin G.R.; Hill A.P.; Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: Discovery of compounds with potential anti-migraine properties. J Med Chem 1995,38(18),3566-3580","journal-title":"J Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1212\/WNL.48.3_Suppl_3.21S","volume":"48","author":"Ferrari M.D.","year":"1997","unstructured":"Ferrari M.D.; 311C90: Increasing the options for therapy with effective acute antimigraine 5HT1B\/1D receptor agonists. Neurology 1997,48(3)(Suppl. 3),S21-S24","journal-title":"Neurology"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2165\/00023210-199707060-00005","volume":"7","author":"Palmer K.J.","year":"1997","unstructured":"Palmer K.J.; Spencer C.M.; Zolmitriptan. CNS Drugs 1997,7(6),468-478","journal-title":"CNS Drugs"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.bjp.0701041","volume":"121","author":"Martin G.R.","year":"1997","unstructured":"Martin G.R.; Robertson A.D.; MacLennan S.J.; Receptor specificity and trigemino-vascular inhibito-ry actions of a novel 5-HT1B\/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 1997,121(2),157-164","journal-title":"Br J Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ejpb.2011.02.014","volume":"78","author":"Bayrak Z.","year":"2011","unstructured":"Bayrak Z.; Tas C.; Tasdemir U.; Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2011,78(3),499-505","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=12","first-page":"373","volume":"2012","author":"Desu P.","year":"2012","unstructured":"Desu P.; Sahu M.; Formulation and evaluation of fast dissolving films of zolmitriptan. Int Res J Pharm 2012,2012(3),373-376","journal-title":"Int Res J Pharm"},{"key":"ref=13","first-page":"7","volume":"2","author":"Bankim C.N.","year":"2013","unstructured":"Bankim C.N.; Gupta A.K.; Mittal A.; Mohd K.Z.; Design and development of solid dispersion system of zolmitriptan. J Biomed Pharm Res 2013,2,7-13","journal-title":"J Biomed Pharm Res"},{"key":"ref=14","first-page":"545","volume":"7","author":"Niranjan P.","year":"2015","unstructured":"Niranjan P.; Reddy A.V.; Reddy G.V.S.; Panda K.C.; Formulation, design and in vitro evaluation of zolmitriptan immediate release tablets using Primojel and AC-Di-Sol. J Pharm Sci Res 2015,7(8),545-553","journal-title":"J Pharm Sci Res"},{"key":"ref=15","first-page":"478","volume":"7","author":"Patil P.R.","year":"2015","unstructured":"Patil P.R.; Salve V.K.; Thorat R.U.; Shahi S.R.; Formulation and evaluation of ion-sensitive in-situ nasal gel of zolmitriptan. Int J Pharma Sci 2015,7,478-486","journal-title":"Int J Pharma Sci"},{"key":"ref=16","author":"Sweetman S.C.","year":"2007","unstructured":"Sweetman S.C.;   The Martindale: The Complete Drug Reference. 35th ed. Vol: USA: Pharmaceutical Press2007"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejps.2009.07.003","volume":"38","author":"Alhalaweh A.","year":"2009","unstructured":"Alhalaweh A.; Andersson S.; Velaga S.P.; Preparation of zolmitriptan-chitosan microparticles by spray drying for nasal delivery. Eur J Pharm Sci 2009,38(3),206-214","journal-title":"Eur J Pharm Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2174\/2210303109666190508083142","volume":"9","author":"Sachan N.","year":"2019","unstructured":"Sachan N.; Bahadur S.; Sharma P.K.; Recent advances and novel approaches for nose to brain drug de-livery for treatment of migraine. Drug Deliv Lett 2019,9(3),182-198","journal-title":"Drug Deliv Lett"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2165\/00044011-200525030-00006","volume":"25","author":"Uemura N.","year":"2005","unstructured":"Uemura N.; Onishi T.; Mitaniyama A.; Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Investig 2005,25(3),199-208","journal-title":"Clin Drug Investig"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1517\/14656566.3.7.993","volume":"3","author":"Dowson A.J.","year":"2002","unstructured":"Dowson A.J.; Charlesworth B.; Review of zolmitriptan and its clinical applications in migraine. Expert Opin Pharmacother 2002,3(7),993-1005","journal-title":"Expert Opin Pharmacother"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/0333102497017S1803","volume":"17","author":"Dixon R.","year":"1997","unstructured":"Dixon R.; Warrander A.; The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997,17(18)(Suppl. 18),15-20","journal-title":"Cephalalgia"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1212\/01.WNL.0000115105.05966.A7","volume":"62","author":"Ahonen K.","year":"2004","unstructured":"Ahonen K.; H\u00e4m\u00e4l\u00e4inen M.L.; Rantala H.; Hoppu K.; Nasal sumatriptan is effective in treatment of mi-graine attacks in children: A randomized trial. Neurology 2004,62(6),883-887","journal-title":"Neurology"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1526-4610.2006.00301.x","volume":"46","author":"Goadsby P.J.","year":"2006","unstructured":"Goadsby P.J.; Yates R.; Zolmitriptan intranasal: A review of the pharmacokinetics and clinical efficacy. Headache 2006,46(1),138-149","journal-title":"Headache"},{"key":"ref=24","first-page":"297","volume":"9","author":"Egla M.","year":"2017","unstructured":"Egla M.; Abd Al, Hammid SN. Design zolmitriptan liquisolid orodispersible tablets and their in vitro evaluation. Int J Pharma Sci 2017,9(1),297-303","journal-title":"Int J Pharma Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/10717544.2013.838713","volume":"21","author":"Mittal D.","year":"2014","unstructured":"Mittal D.; Ali A.; Md S.; Baboota S.; Sahni J.K.; Ali J.; Insights into direct nose to brain delivery: Current status and future perspective. Drug Deliv 2014,21(2),75-86","journal-title":"Drug Deliv"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3797\/scipharm.1208-18","volume":"81","author":"Gulati N.","year":"2013","unstructured":"Gulati N.; Nagaich U.; Saraf S.A.; Intranasal delivery of chitosan nanoparticles for migraine therapy. Sci Pharm 2013,81(3),843-854","journal-title":"Sci Pharm"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/jps.21924","volume":"99","author":"Dhuria S.V.","year":"2010","unstructured":"Dhuria S.V.; Hanson L.R.; Frey W.H.; Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci 2010,99(4),1654-1673","journal-title":"J Pharm Sci"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","volume":"12","author":"Pires A.","year":"2009","unstructured":"Pires A.; Fortuna A.; Alve G.; Falcao A.; Intranasal drug delivery: How, why and what for? J Pharm Pharm Sci 2009,12(3),288-311","journal-title":"J Pharm Pharm Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1567201815666181004094707","volume":"16","author":"Sunena M.","year":"2019","unstructured":"Sunena M.; Singh S.K.; Mishra D.N.; Nose to brain delivery of galantamine loaded nanoparticles: In-vivo pharmacodynamic and biochemical study in mice. Curr Drug Deliv 2019,16(1),51-58","journal-title":"Curr Drug Deliv"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0169-409X(00)00122-8","volume":"47","author":"Kreuter J.","year":"2001","unstructured":"Kreuter J.; Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001,47(1),65-81","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","volume":"379","author":"Mistry A.","year":"2009","unstructured":"Mistry A.; Stolnik S.; Illum L.; Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009,379(1),146-157","journal-title":"Int J Pharm"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.1021\/acsomega.0c00111","volume":"5","author":"Far J.","year":"2020","unstructured":"Far J.; Abdel-Haq M.; Gruber M.; Abu Ammar A.; Developing biodegradable nanoparticles loaded with mometasone furoate for potential nasal drug delivery. ACS Omega 2020,5(13),7432-7439","journal-title":"ACS Omega"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101919","volume":"59","author":"Esim O.","year":"2020","unstructured":"Esim O.; Savaser A.; Ozkan C.K.; Nose to brain delivery of eletriptan hydrobromide nanoparticles: Preparation, in vitro\/in vivo evaluation and effect on trigeminal activation. J Drug Deliv Sci Technol 2020,59","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=34","first-page":"707","volume":"71","author":"Bhanushali R.S.","year":"2009","unstructured":"Bhanushali R.S.; Gatne M.M.; Gaikwad I.R.V.; Bajaj A.N.; Morde M.A.; Nanoemulsion based intranasal delivery of antimigraine drugs for nose to brain targeting. Indian J Pharm Sci 2009,71,707-709","journal-title":"Indian J Pharm Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","volume":"6","author":"Gao H.","year":"2016","unstructured":"Gao H.; Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B 2016,6(4),268-286","journal-title":"Acta Pharm Sin B"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202004025","volume":"8","author":"Ruan S.","year":"2021","unstructured":"Ruan S.; Zhou Y.; Jiang X.; Gao H.; Rethinking CRITID procedure of brain targeting drug delivery: Circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internaliza-tion, and drug release. Adv Sci (Weinh) 2021,8(9)","journal-title":"Adv Sci (Weinh)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/9781119041450.ch2","author":"Girotra P.","year":"2015","unstructured":"Girotra P.; Singh S.K.;  Handbook of Polymers for Pharmaceutical Technologies Wiley: Scrivener Publish-ing LLC In: Thakur VK, Thakur MK, Eds. 2015,33-60","journal-title":"Handbook of Polymers for Pharmaceutical Technologies Wiley: Scrivener Publish-ing LLC"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1023\/B:PHAM.0000012150.60180.e3","volume":"21","author":"Smith J.","year":"2004","unstructured":"Smith J.; Wood E.; Dornish M.; Effect of chitosan on epithelial cell tight junctions. Pharm Res 2004,21(1),43-49","journal-title":"Pharm Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1023\/A:1018830204170","volume":"16","author":"Bernkop-Schn\u00fcrch A.","year":"1999","unstructured":"Bernkop-Schn\u00fcrch A.; Schwarz V.; Steininger S.; Polymers with thiol groups: A new generation of mu-coadhesive polymers? Pharm Res 1999,16(6),876-881","journal-title":"Pharm Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0939-6411(03)00147-4","volume":"57","author":"Bernkop-Schn\u00fcrch A.","year":"2004","unstructured":"Bernkop-Schn\u00fcrch A.; Hornof M.; Guggi D.; Thiolated chitosans. Eur J Pharm Biopharm 2004,57(1),9-17","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/(SICI)1099-0488(20000201)38:3<369::AID-POLB3>3.0.CO;2-W","volume":"38","author":"Rana D.","year":"2000","unstructured":"Rana D.; Bag K.; Bhattacharyya S.N.; Mandal B.M.; Miscibility of poly(styrene-co-butyl acrylate) with poly(ethyl methacrylate): Existence of both UCST and LCST. J Polym Sci, B, Polym Phys 2000,38(3),369-375","journal-title":"J Polym Sci, B, Polym Phys"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/0032-3861(96)85356-0","volume":"37","author":"Rana D.","year":"1996","unstructured":"Rana D.; Mandal B.M.; Bhattacharyya S.N.; Analogue calorimetry of polymer blends: Poly(styrene-co-acrylonitrile) and poly(phenyl acrylate) or poly(vinyl benzoate). Polymer (Guildf) 1996,37(12),2439-2443","journal-title":"Polymer (Guildf)"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/0032-3861(93)90861-4","volume":"34","author":"Rana D.","year":"1993","unstructured":"Rana D.; Mandal B.M.; Bhattacharyya S.N.; Miscibility and phase diagrams of poly(phenyl acrylate) and poly(styrene-co-acrylonitrile) blends. Polymer (Guildf) 1993,34(7),1454-1459","journal-title":"Polymer (Guildf)"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1021\/ma950954n","volume":"29","author":"Rana D.","year":"1996","unstructured":"Rana D.; Mandal B.M.; Bhattacharyya S.N.; Analogue calorimetric studies of blends of poly (vinyl ester) and polyacrylates. Macromolecules 1996,29(5),1579-1583","journal-title":"Macromolecules"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejpb.2006.01.002","volume":"63","author":"Bernkop-Schn\u00fcrch A.","year":"2006","unstructured":"Bernkop-Schn\u00fcrch A.; Heinrich A.; Greimel A.; Development of a novel method for the preparation of submicron particles based on thiolated chitosan. Eur J Pharm Biopharm 2006,63(2),166-172","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.2147\/DDDT.S220473","volume":"13","author":"El-Nabarawy N.A.","year":"2019","unstructured":"El-Nabarawy N.A.; Teaima M.H.; Helal D.A.; Assessment of spanlastic vesicles of zolmitriptan for treat-ing migraine in rats. Drug Des Devel Ther 2019,13,3929-3937","journal-title":"Drug Des Devel Ther"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.drudis.2017.04.016","volume":"22","author":"Munro G.","year":"2017","unstructured":"Munro G.; Jansen-Olesen I.; Olesen J.; Animal models of pain and migraine in drug discovery. Drug Discov Today 2017,22(7),1103-1111","journal-title":"Drug Discov Today"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.3390\/ijms20122932","volume":"20","author":"Tardiolo G.","year":"2019","unstructured":"Tardiolo G.; Bramanti P.; Mazzon E.; Migraine: Experimental models and novel therapeutic approaches. Int J Mol Sci 2019,20(12),2932","journal-title":"Int J Mol Sci"},{"key":"ref=49","first-page":"1341","volume":"7","year":"2016","unstructured":"Sunena, Mishra DN, Singh SK, Kumar A. Synthesis, characterization and in vitro evaluation of muco-adhesive potential of thiolated chitosan. Inter J Pharma Prof Res 2016,7(5),1341-1345","journal-title":"Inter J Pharma Prof Res"},{"key":"ref=50","first-page":"206","volume":"8","year":"2016","unstructured":"Sunena, Mishra DN, Singh SK, Kumar A. Formulation and optimization of mucoadhesive galanta-mine loaded nanoparticles. Pharm Lett 2016,8(10),206-212","journal-title":"Pharm Lett"},{"key":"ref=51","first-page":"19","volume":"5","year":"2016","unstructured":"Sunena, Mishra DN, Singh SK, Kumar A. Development and characterization of zolmitriptan thiolated chitosan nanoparticles for intranasal drug delivery. Pharma Innov J 2016,5(7),19-23","journal-title":"Pharma Innov J"},{"key":"ref=52","first-page":"248","volume":"9","author":"Sunena Jalwal P.","year":"2020","unstructured":"Sunena Jalwal P.; Nose to brain drug delivery of nanoformulations in the treatment of migraine. Pharma Innovation Journal 2020,9(12),248-253","journal-title":"Pharma Innovation Journal"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0169-409X(00)00123-X","volume":"47","author":"Janes K.A.","year":"2001","unstructured":"Janes K.A.; Calvo P.; Alonso M.J.; Polysaccharide colloidal particles as delivery systems for macromole-cules. Adv Drug Deliv Rev 2001,47(1),83-97","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/10717540590889781","volume":"12","author":"Prabaharan M.","year":"2005","unstructured":"Prabaharan M.; Mano J.F.; Chitosan-based particles as controlled drug delivery systems. Drug Deliv 2005,12(1),41-57","journal-title":"Drug Deliv"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jconrel.2014.06.053","volume":"189","author":"Kozlovskaya L.","year":"2014","unstructured":"Kozlovskaya L.; Abou-Kaoud M.; Stepensky D.; Quantitative analysis of drug delivery to the brain via nasal route. J Control Release 2014,189,133-140","journal-title":"J Control Release"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-5173(03)00341-7","volume":"263","author":"Wang F.","year":"2003","unstructured":"Wang F.; Jiang X.; Lu W.; Profiles of methotrexate in blood and CSF following intranasal and intrave-nous administration to rats. Int J Pharm 2003,263(1-2),1-7","journal-title":"Int J Pharm"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"21585","DOI":"10.1021\/acsami.6b06903","volume":"8","author":"Zheng T.","year":"2016","unstructured":"Zheng T.; Bott S.; Huo Q.; Techniques for accurate sizing of gold nanoparticles using dynamic light scattering with particular application to chemical and biological sensing based on aggregate formation. ACS Appl Mater Interfaces 2016,8(33),21585-21594","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=58","first-page":"119","volume":"6","author":"Saremi S.","year":"2011","unstructured":"Saremi S.; Atyabi F.; Akhlaghi S.P.; Ostad S.N.; Dinarvand R.; Thiolated chitosan nanoparticles for en-hancing oral absorption of docetaxel: Preparation, in vitro and ex vivo evaluation. Int J Nanomedicine 2011,6,119-128","journal-title":"Int J Nanomedicine"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40005-016-0233-4","volume":"46","author":"Lee C.A.","year":"2016","unstructured":"Lee C.A.; Kim B.S.; Cho C.W.; Quantitative evaluation of mucoadhesive polymers to compare the muco-adhesion. J Pharm Investig 2016,46(2),189-194","journal-title":"J Pharm Investig"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejpb.2007.01.010","volume":"67","author":"Thirawong N.","year":"2007","unstructured":"Thirawong N.; Nunthanid J.; Puttipipatkhachorn S.; Sriamornsak P.; Mucoadhesive properties of various pectins on gastrointestinal mucosa: An in vitro evaluation using texture analyzer. Eur J Pharm Biopharm 2007,67(1),132-140","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.neuroscience.2009.03.003","volume":"160","author":"Okamoto K.","year":"2009","unstructured":"Okamoto K.; Thompson R.; Tashiro A.; Chang Z.; Bereiter D.A.; Bright light produces Fos-positive neu-rons in caudal trigeminal brainstem. Neuroscience 2009,160(4),858-864","journal-title":"Neuroscience"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0963-6","volume":"20","author":"Vuralli D.","year":"2019","unstructured":"Vuralli D.; Wattiez A.S.; Russo A.F.; Bolay H.; Behavioral and cognitive animal models in headache re-search. J Headache Pain 2019,20(11)","journal-title":"J Headache Pain"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.pain.2008.06.002","volume":"139","author":"Nikai T.","year":"2008","unstructured":"Nikai T.; Basbaum A.I.; Ahn A.H.; Profound reduction of somatic and visceral pain in mice by intrathe-cal administration of the anti-migraine drug, sumatriptan. Pain 2008,139(3),533-540","journal-title":"Pain"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ana.20193","volume":"56","author":"Bartsch T.","year":"2004","unstructured":"Bartsch T.; Knight Y.E.; Goadsby P.J.; Activation of 5-HT(1B\/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004,56(3),371-381","journal-title":"Ann Neurol"}],"container-title":["Pharmaceutical Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2211738510666220303160414","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/201669\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2211738510666220303160414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T03:39:13Z","timestamp":1692934753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/201669\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2211738510666220303160414","relation":{},"ISSN":["2211-7385"],"issn-type":[{"value":"2211-7385","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}